On June 12, 2026, the Trump administration revealed its intention to tackle a loophole in the Medicare drug price negotiation process.
This policy is designed to enhance negotiations and potentially lower costs for Medicare beneficiaries.
The changes may also have implications for pharmaceutical companies, as the administration seeks to improve the affordability of medications.